Paricalcitol
- Generic Name
- Paricalcitol
- Brand Names
- Zemplar
- Drug Type
- Small Molecule
- Chemical Formula
- C27H44O3
- CAS Number
- 131918-61-1
- Unique Ingredient Identifier
- 6702D36OG5
- Background
Paricalcitol is a synthetic vitamin D analog. Paricalcitol has been used to reduce parathyroid hormone levels. Paricalcitol is indicated for the prevention and treatment of secondary hyperparathyroidism associated with chronic renal failure.
- Indication
For treatment of secondary hyperparathyroidism associated with chronic kidney disease (CKD) Stage 3 and 4
- Associated Conditions
- Secondary Hyperparathyroidism (SHPT)
- Associated Therapies
- -
Oral Paricalcitol in Kidney Transplant Recipients
- Conditions
- Interventions
- First Posted Date
- 2008-01-07
- Last Posted Date
- 2013-05-13
- Lead Sponsor
- Mayo Clinic
- Target Recruit Count
- 100
- Registration Number
- NCT00587158
- Locations
- 🇺🇸
Mayo Clinic, Rochester, Minnesota, United States
The PRIMO Study: Paricalcitol Capsules Benefits Renal Failure Induced Cardiac Morbidity in Subjects With Chronic Kidney Disease Stage 3/4
- Conditions
- Interventions
- First Posted Date
- 2007-07-06
- Last Posted Date
- 2013-03-12
- Lead Sponsor
- AbbVie (prior sponsor, Abbott)
- Target Recruit Count
- 227
- Registration Number
- NCT00497146
- Locations
- 🇷🇺
Site Reference ID/Investigator# 7251, Moscow, Russian Federation
🇨🇳Site Reference ID/Investigator# 8228, Taipei, Taiwan
🇷🇴Site Reference ID/Investigator# 8881, Bucharest, Romania
Treatment of Secondary Hyperparathyroidism in the Uremic Patient
- Conditions
- Interventions
- First Posted Date
- 2007-05-04
- Last Posted Date
- 2011-04-04
- Lead Sponsor
- Zealand University Hospital
- Target Recruit Count
- 86
- Registration Number
- NCT00469599
- Locations
- 🇩🇰
Aalborg University Hospital, Aalborg, Denmark
🇩🇰Århus University Hospital Skejby, Aarhus, Denmark
🇩🇰Hospital of Southwest Denmark Esbjerg, Esbjerg, Denmark
Study of Protective Effects of Paricalcitol on Inner Layer of Vessels and Its Protective Effect on Inflammation
- Conditions
- Interventions
- First Posted Date
- 2007-01-29
- Last Posted Date
- 2009-06-03
- Lead Sponsor
- Indiana University School of Medicine
- Target Recruit Count
- 24
- Registration Number
- NCT00428246
- Locations
- 🇺🇸
Richard A. Rodebush VA Medical Center, Indianapolis, Indiana, United States
Effectiveness of Paricalcitol in Reducing Parathyroid Hormone (PTH) Levels in X-linked Hypophosphatemic Rickets
- Conditions
- Interventions
- First Posted Date
- 2007-01-01
- Last Posted Date
- 2020-03-17
- Lead Sponsor
- Yale University
- Target Recruit Count
- 33
- Registration Number
- NCT00417612
- Locations
- 🇺🇸
Yale University School of Medicine, New Haven, Connecticut, United States
Initial Dosing of Paricalcitol in Secondary Hyperparathyroidism
- Conditions
- First Posted Date
- 2006-03-28
- Last Posted Date
- 2006-03-28
- Lead Sponsor
- Papageorgiou General Hospital
- Registration Number
- NCT00307840
Effect of Paricalcitol on Markers of Inflammation in Hemodialysis Patients
- First Posted Date
- 2006-02-22
- Last Posted Date
- 2010-04-08
- Lead Sponsor
- Fresenius Medical Care North America
- Target Recruit Count
- 64
- Registration Number
- NCT00294866
- Locations
- 🇺🇸
Nephrology Center, Kalamazoo, Michigan, United States
🇺🇸Delaware Valley Nephrology, Philadelphia, Pennsylvania, United States
🇺🇸Nephrology Associates, PC, Nashville, Tennessee, United States
Paricalcitol and Zoledronate in Treating Patients With Relapsed or Refractory Multiple Myeloma or Other Plasma Cell Disorders
- Conditions
- First Posted Date
- 2005-11-24
- Last Posted Date
- 2013-02-01
- Lead Sponsor
- Roswell Park Cancer Institute
- Target Recruit Count
- 7
- Registration Number
- NCT00258258
- Locations
- 🇺🇸
Roswell Park Cancer Institute, Buffalo, New York, United States
Paricalcitol and Gemcitabine in Treating Patients With Advanced Cancer
- Conditions
- Interventions
- First Posted Date
- 2005-09-22
- Last Posted Date
- 2014-12-09
- Lead Sponsor
- Roswell Park Cancer Institute
- Target Recruit Count
- 34
- Registration Number
- NCT00217477
- Locations
- 🇺🇸
Roswell Park Cancer Institute, Buffalo, New York, United States
Study to Compare Initial Dosing Parameters of Zemplar in Stage V Chronic Kidney Disease Subjects on Hemodialysis
- Conditions
- First Posted Date
- 2004-09-13
- Last Posted Date
- 2007-09-26
- Lead Sponsor
- Abbott
- Target Recruit Count
- 201
- Registration Number
- NCT00091481
- Locations
- 🇬🇷
General Hospital of Heraklion, Voutes, Heraklion, Crete, Greece
🇬🇷General Hospital of Melissia "Amalia Fleming", Melissia, Athens, Greece
🇬🇷General University Hospital of Alexandroupolis, Dragana, Greece
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.